• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MICRO THERAPEUTICS, INC. DBA EV3 PIPELINE INTRACRANIAL ANEURYSM FLOW DIVERTER

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MICRO THERAPEUTICS, INC. DBA EV3 PIPELINE INTRACRANIAL ANEURYSM FLOW DIVERTER Back to Search Results
Model Number NV UNK PIPELINE
Device Problems Positioning Failure (1158); Activation, Positioning or Separation Problem (2906); Adverse Event Without Identified Device or Use Problem (2993); Unintended Movement (3026); Activation Failure (3270); Migration (4003)
Patient Problems Stroke/CVA (1770); Hemorrhage/Bleeding (1888); Unspecified Nervous System Problem (4426)
Event Date 12/08/2020
Event Type  Death  
Manufacturer Narrative
If information is provided in the future, a supplemental report will be issued.
 
Event Description
Huibin kang, yu zhou, bin luo, nan lv, hongqi zhang, tianxiao li, donglei song, yuanli zhao, sheng guan, aisha maimaitili, yunyan wang, wenfeng feng, yang wang, jieqing wan, guohua mao, huaizhang shi, xinjian yang, and jianmin liu; neurotherapeutics; 2021; 18:1198-1206; pipeline embolization device for intracranial aneurysms in a large chinese cohort: complication risk factor analysis; https:/ /doi. Org/10. 1007/s13311-020-00990 medtronic received information in literature of complications in the use if pipeline ped stents in patient treated for intercranial aneurysms  between november 2014 and october 2019 in 14 centers across china.  a total of 1171 consecutive patients (mean age, 53. 9 ± 11. 4; female, 69. 6%[813/1171]) with 1322 aneurysms were included in the study. Embolization procedures involved the use of the classic or flex ped. The ped was delivered and deployed through a marksman microcatheter.  additional techniques, including the use of adjunctive coils, overlapping peds, and balloon angioplasty, were applied according to the operator¿s preference and experience. The protocol did not specify the coiling methodology, and the decision to use coils with the ped was left to the discretion of the treating physician.  patients were administered an antiplatelet regimen that included a combination of aspirin (100¿300 mg daily) and clopidogrel (75 mg daily); however, patients who were identified as clopidogrel non-responders were administered aspirin (100 mg daily) and ticagrelor (90 mg twice daily). The dose of aspirin/clopidogrel was adjusted preoperatively after platelet function testing.  the mean aneurysm size, neck size, and parent artery diameter was 12. 79 ± 8. 75 mm, 6. 21 ± 3. 92 mm, and 3. 88 ± 0. 82 mm, respectively.  the morphology of aneurysms was saccular in 83. 1% (1099/1322), fusiform in 8. 2% (109/1322), dissecting in 6. 3% (83/1322), and blister in 2. 3% (31/1322) of cases. The majority of occlusions were located in the anterior circulation (proximal, 83. 6% [1105/1322]; distal, 3. 6% [48/1322]), while 12. 8% (169/1322) were located in the posterior circulation, including 2. 2% (29/1322) in the basilar artery and 10. 6% (140/1322) in the vertebral artery and other vessels in the posterior circulation.  device deployment to the target site was considered unsuccessful when ped opening failed or when the ped was deployed inside the aneurysm. Successful device deployment to the target site after adjustment was defined when the ped was released successfully after technical adjustments. Device deployment to the target site was considered successful when the ped was released successfully at the target location without technical adjustments. The classic and flex peds were used in similar proportions (45. 2% [596/1322] vs. 54. 8% [723/1322], respectively). The diameter and length of the device was 4. 07 ± 0. 53 mm and 25. 37 ± 5. 76 mm, respectively.  at the last follow-up for each patient, the total occlusion rate was 81. 4% (787/967), 91. 6% (1211/1322) of parent arteries were patent, 7. 0% (93/1322) of parent arteries were stenotic, and 1. 4% (18/1322) of parent arteries were occluded. A total of 93. 9% (1241/1322) of peds were successfully deployed to the target site, and the rate of complete occlusion immediately after the operation was 14. 6%.  the mrs score was 0¿2 and 3¿6 before ped treatment in 1060 (90. 5%) and 111 (9. 5%) cases, respectively. The mrs score was 0¿2 and 3¿6 in the early postoperative in 1094 93. 4%) and 77 (6. 6%) cases, respectively. The mrs score was 0¿2 and 3¿6 at follow-up in 1111 (94. 9%) and 60 (5. 1%) cases, respectively.  balloon angioplasty 31 (2. 3%).  unsuccessful 10 (0. 8%).   events were documented at less than 30 days and than again between 3 and 36 months:  major ischemic stroke 44 (3. 8%), 7 (0. 6%); tia/minor stroke 30 (2. 6%), 4 (0. 3%); delayed aneurysm rupture (dar) 23 (2. 0%), 1 (0. 1%)' distal intraparenchymal hemorrhage (diph) 23 (2. 0%), 0 (0%); stent migration 9 (0. 8%), 0 (0%); access site complications 41 (3. 5%). 0 (0%); neurological compressive symptoms 44 (3. 8%), 7 (0. 6%); mortality 15 (1. 3%), 2 (0. 2%); poor functional outcome, mrs score 3¿6 77 (6. 6%), 60 (5. 1%).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand NamePIPELINE
Type of DeviceINTRACRANIAL ANEURYSM FLOW DIVERTER
Manufacturer (Section D)
MICRO THERAPEUTICS, INC. DBA EV3
9775 toledo way
irvine CA 92618
Manufacturer (Section G)
MICRO THERAPEUTICS, INC. DBA EV3
9775 toledo way
irvine CA 92618
Manufacturer Contact
glen belmer
9775 toledo way
irvine, CA 92618
6122713209
MDR Report Key13420213
MDR Text Key284856177
Report Number2029214-2022-00135
Device Sequence Number1
Product Code OUT
Combination Product (y/n)N
Reporter Country CodeCH
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Literature,Health Professional
Reporter Occupation
Type of Report Initial
Report Date 02/01/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received02/02/2022
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator
Device Model NumberNV UNK PIPELINE
Device Catalogue NumberNV UNK PIPELINE
Device Lot NumberUNKNOWN
Was Device Available for Evaluation? No
Date Manufacturer Received01/28/2022
Was Device Evaluated by Manufacturer? No Answer Provided
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial

Patient Treatment Data
Date Received: 02/02/2022 Patient Sequence Number: 1
-
-